iii) at least one biocompatible, oxygen containing, low viscosity organic solvent;

wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture, in the manufacture of a pre-formulation for use in the sustained administration of said active agent, wherein said pre-formulation is capable of forming at least one non-lamellar liquid crystalline phase structure upon contact with an aqueous fluid.

32. The use according to claim 31 wherein component i) comprises a sorbitan ester, preferably a mixture comprising fatty acid mono-, di- and tri-esters of sorbitan.

33. A method of treatment or prophylaxis of a human or non-human animal subject comprising administration of a pre-formulation as claimed in any of claims 1 to 22.

34. A pre-filled administration device containing a pre-formulation as claimed in any of claims 1 to 22.

35. The device as claimed in claim 34 being a syringe or syringe barrel, a needle-less injector, a multi- or single-use injector, a cartridge or a vial.

36. The device of claims 34 or 35 equipped with an injection aid, such as an auto-injector.

37. A kit comprising an administration device as claimed in any of claims 34 to 36.

38. A method of delivery of a pre-formulation to a subject in need thereof, the method involving administering a pre-formulation as claimed in any of claims 1 to 22 using an administration device as claimed in any of claims 34-36.